Search results for "Organo"

showing 10 items of 1460 documents

The Carbon Monoxide-Releasing Molecule Tricarbonyldichlororuthenium(II) Dimer Protects Human Osteoarthritic Chondrocytes and Cartilage from the Catab…

2008

We have investigated the effects of a carbon monoxide-releasing molecule, tricarbonyldichlororuthenium(II) dimer (CORM-2), on catabolic processes in human osteoarthritis (OA) cartilage and chondrocytes activated with interleukin-1beta. In these cells, proinflammatory cytokines induce the synthesis of matrix metalloproteinases (MMPs) and aggrecanases, including members of a disintegrin and metalloproteinase with thrombospondin domain (ADAMTS) family, which may contribute to cartilage loss. CORM-2 down-regulated MMP-1, MMP-3, MMP-10, MMP-13, and ADAMTS-5 in OA chondrocytes, and it inhibited cartilage degradation. These effects were accompanied by increased aggrecan synthesis and collagen II e…

MaleInterleukin-1betaDown-RegulationMatrix metalloproteinaseProtective AgentsProinflammatory cytokineExtracellular matrixChondrocytesOsteoarthritisOrganometallic CompoundsmedicineExtracellularHumansAggrecansCollagen Type IIAggrecanAgedPharmacologyCarbon MonoxideThrombospondinChemistryCartilageADAMTSMatrix MetalloproteinasesCell biologyCartilagemedicine.anatomical_structureBiochemistryMolecular MedicineFemaleJournal of Pharmacology and Experimental Therapeutics
researchProduct

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European rand…

2021

Abstract Background In colon cancer (CC), surgery remains the mainstay of treatment with curative intent. Despite several clinical trials comparing open and laparoscopic approaches, data on long-term outcomes for stage III CC are lacking. Methods This post-hoc analysis of the European PETACC8 randomized phase 3 trial included patients from 340 sites between December 2005 and November 2009, with long follow-up (median 7.56 years). Patients were randomly assigned to FOLFOX or FOLFOX+cetuximab after colonic resection. The surgical approach was left to the referring surgeon's discretion. Results Among 2555 patients included, 1796 (70.29%) were operated on by open surgery and 759 (29.71%) by lap…

MaleLaparoscopic surgerymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLeucovorinCetuximabAntineoplastic AgentsDisease-Free Survivallaw.invention03 medical and health sciences0302 clinical medicineFOLFOXRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Propensity ScoreLaparoscopyColectomyAgedNeoplasm StagingColectomyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyPrognosismedicine.diseaseSurgeryEuropeSurvival RateClinical trialTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisFemaleLaparoscopy030211 gastroenterology & hepatologyFluorouracilbusinessFollow-Up Studiesmedicine.drugDigestive and Liver Disease
researchProduct

Influence of intravenously administered lidocaine on cerebral blood flow in a baboon model standardized under controlled general anaesthesia using si…

1993

The baboon under general anaesthesia as a model to assess drug-induced cerebral blood flow changes (delta CBF) using single-photon emission tomography (SPET) offers great in vivo possibilities but has to comply with demands on control of anaesthesia-related influencing factors, such as PaCO2 changes. The model sought in this study and described here allows control of PaCO2, in the baboon under thiopentone anaesthesia by ventilation, and was evaluated for the functional dependence of delta CBF vs delta PaCO2, using SPET technetium-99m hexamethylpropylene amine oxime (HMPAO) and the split-dose method together with controlled ventilation. During the experiment the model was validated for norma…

MaleLidocaineRespiratory rateHemodynamicsAnesthesia GeneralModels BiologicalTechnetium Tc 99m Exametazimebiology.animalOximesmedicineAnimalsRadiology Nuclear Medicine and imagingTomography Emission-Computed Single-Photonbiologybusiness.industryLidocaineGeneral MedicineBlood flowOrganotechnetium CompoundsBlood pressureCerebral blood flowAnesthesiaCerebrovascular CirculationInjections IntravenousBreathingbusinessmedicine.drugBaboonPapioEuropean journal of nuclear medicine
researchProduct

Organometallic complexes with biological molecules. XVII. Triorganotin(IV) complexes with amoxicillin and ampicillin.

2002

Novel triorganotin(IV) complexes of two β-lactamic antibiotics, 6-[D-(-)-β-amino-p-hydroxyphenyl-acetamido]penicillin (=amoxicillin) and 6-[D-(-)-α-aminobenzyl]penicillin (=ampicillin), have been synthesized and investigated both in solid and solution states. The complexes corresponded to the general formula R3Sn(IV)antib·H2O (R=Me, n-Bu, Ph; antib=amox=amoxicillinate or amp=ampicillinate). Structural investigations about configuration in the solid state have been carried out by interpreting experimental IR and 119Sn Mössbauer data. In particular, IR results suggested polymeric structures both for R3Sn(IV)amox·H2O and R3Sn(IV)amp·H2O. Moreover, both antibiotics appear to behave as monoanion…

MaleMagnetic Resonance SpectroscopySpectrophotometry InfraredOrganotin(IV) complexeAmoxicillinPenicillinBiochemistryBiological moleculeChromosomesBivalviaInorganic ChemistrySolutionsStructure-Activity RelationshipSettore CHIM/03 - Chimica Generale E InorganicaSpermatocytesThermogravimetryOrganotin CompoundsAnimalsAmpicillinDNA DamageJournal of inorganic biochemistry
researchProduct

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chem…

2014

Background & Aims Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy. A dominant-negative form of heat shock protein (HSP)110 (HSP110DE9) expressed by cancer cells with MSI, via exon skipping caused by somatic deletions in the T 17 intron repeat, sensitizes the cells to 5-fluorouracil and oxaliplatin. We investigated whether HSP110 T 17 could be used to identify patients with colorectal cancer who would benefit from adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Methods We characterized the interaction between HSP110 and HSP110DE9 using su…

MaleModels MolecularOrganoplatinum CompoundsColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Leucovorin0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsHSP110 Heat-Shock ProteinsComputingMilieux_MISCELLANEOUSColectomySequence Deletion0303 health sciencesGastroenterologyPrimary tumor3. Good healthOxaliplatinTreatment OutcomeFluorouracilChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityFluorouracilColorectal Neoplasmsmedicine.drugBlotting WesternAntineoplastic AgentsBiology03 medical and health sciencesCell Line TumormedicineBiomarkers TumorHumans030304 developmental biologyAgedRetrospective StudiesChemotherapyHepatologyBase SequenceMicrosatellite instabilityCancerSurface Plasmon Resonancemedicine.diseaseMolecular biologySurvival AnalysisIntronsOxaliplatinCancer cellCancer researchFollow-Up StudiesGastroenterology
researchProduct

Childhood neuromuscular disease with rimmed vacuoles

1986

A 5-year-old boy suffered from a slowly progressive non-familial neuromuscular disease, clinically marked by generalised muscle weakness, atrophy and hypotonia, a "myopathic" EMG and mildly elevated CK values. His gastrocnemius muscle showed marked myopathy, type I fibre predominance, and numerous "rimmed" vacuoles. This boy's condition is regarded as a childhood neuromuscular disease with rimmed vacuoles.

MaleNeuromuscular diseasemedicine.diagnostic_testbusiness.industryMusclesRimmed vacuolesMuscle weaknessNeuromuscular DiseasesAnatomymedicine.diseaseHypotoniaOrganoidsGastrocnemius muscleAtrophyChild PreschoolVacuolesPediatrics Perinatology and Child HealthBiopsymedicineHumansmedicine.symptombusinessMyopathyEuropean Journal of Pediatrics
researchProduct

Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results

2012

PURPOSE: This study was undertaken to compare response evaluation criteria in solid tumours (RECIST) 1.1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment. METHODS AND MATERIALS: Seventeen patients (12 men, 5 women; mean age 69 years; age range 58-79 years) were included. Tumour response was assessed according to RECIST and mRECIST. Two readers placed a region of interest (ROI) within each target lesion, on the portion showing enhancement during the arterial phase. The lesion attenuation values measured within the ROIs on computed tomography or the signal inten…

MaleNiacinamideSorafenibTarget lesionmedicine.medical_specialtyCarcinoma HepatocellularContrast MediaMeglumineOrganometallic CompoundsCarcinomamedicineHumansRadiology Nuclear Medicine and imagingAgedNeuroradiologymedicine.diagnostic_testbusiness.industryPhenylurea CompoundsLiver NeoplasmsLiver CT MR HCC SorafenibMagnetic resonance imagingGeneral MedicineMiddle AgedSorafenibmedicine.diseaseMagnetic Resonance ImagingIopamidolTreatment OutcomeHepatocellular carcinomaMann–Whitney U testFemaleRadiologyTomography X-Ray ComputedbusinessProgressive diseasemedicine.drugLa radiologia medica
researchProduct

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors

2019

Combinations of therapies may enhance therapeutic effects without significantly increasing the incidence of adverse events. However, there are few data regarding survival after concomitant chemotherapy and peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-octreotate in patients with neuroendocrine tumors (NETs). Thus, we explored the outcome of this combination of therapies.Fifteen patients with somatostatin receptor-positive, rapidly progressive G2/G3 NETs during chemotherapy or PRRT alone from 2 German cancer centers were included in the retrospective analysis. The patients received a combination of PRRT and chemotherapy with temozolomide (n = 3) or temozolomide plus capecitabine (…

MaleOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyPeptide receptormedicine.medical_treatmentNeuroendocrine tumorsOctreotide030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographyInternal medicineOrganometallic CompoundsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingAdverse effectCapecitabineAgedChemotherapybusiness.industryIncidence (epidemiology)Therapeutic effectChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumors030220 oncology & carcinogenesisConcomitantRadionuclide therapyFemaleRadiopharmaceuticalsbusinessClinical Nuclear Medicine
researchProduct

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuxim…

2012

Purpose To evaluate the addition of cetuximab to neoadjuvant chemotherapy before chemoradiotherapy in high-risk rectal cancer. Patients and Methods Patients with operable magnetic resonance imaging–defined high-risk rectal cancer received four cycles of capecitabine/oxaliplatin (CAPOX) followed by capecitabine chemoradiotherapy, surgery, and adjuvant CAPOX (four cycles) or the same regimen plus weekly cetuximab (CAPOX+C). The primary end point was complete response (CR; pathologic CR or, in patients not undergoing surgery, radiologic CR) in patients with KRAS/BRAF wild-type tumors. Secondary end points were radiologic response (RR), progression-free survival (PFS), overall survival (OS), an…

MaleOncologyCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCetuximabKaplan-Meier Estimatemedicine.disease_causeDeoxycytidineGastroenterologyIntestinal mucosaAntineoplastic Combined Chemotherapy ProtocolsIntestinal MucosaColectomyNeoadjuvant therapyCetuximabAntibodies MonoclonalMiddle AgedCombined Modality TherapyNeoadjuvant TherapyOxaliplatinTreatment OutcomeOncologyFemaleFluorouracilKRASmedicine.drugAdultmedicine.medical_specialtyAdenocarcinomaAntibodies Monoclonal HumanizedRisk AssessmentDisease-Free SurvivalCapecitabineInternal medicinePreoperative CaremedicineHumansNeoplasm InvasivenessneoplasmsCapecitabineAgedNeoplasm StagingAnalysis of VarianceRectal Neoplasmsbusiness.industryChemoradiotherapy Adjuvantmedicine.diseaseSurvival AnalysisUnited Kingdomdigestive system diseasesOxaliplatinLogistic ModelsRadiotherapy AdjuvantbusinessChemoradiotherapyFollow-Up StudiesJournal of Clinical Oncology
researchProduct

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in pat…

2013

Abstract Background This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction. Methods Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m2 at dose level (DL) 1 and 2, 25 mg/m2 at DL 3) and oxaliplatin (40 mg/m2 at DL 1, 50 mg/m2 at DL 2 and 3) over 5 weeks. The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall response rate (ORR) and progression-free survival (PFS). Results A total of 24 patients were included. F…

MaleOncologyCancer ResearchTime FactorsEsophageal NeoplasmsOrganoplatinum Compoundsmedicine.medical_treatmentMedizinKaplan-Meier EstimateDocetaxellaw.inventionRandomized controlled triallawGermanyProspective StudiesIsraelProspective cohort studyNeoadjuvant therapyChemoradiotherapyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensNeoadjuvant TherapyOxaliplatinOesophagogastric cancer oxaliplatinTreatment OutcomeDocetaxelOncologyNeoadjuvant radiochemotherapyAdenocarcinomaFemaleTaxoidsEsophagogastric JunctiontherapeuticsResearch Articlemedicine.drugAdultmedicine.medical_specialtyMaximum Tolerated DoseAntineoplastic AgentsAdenocarcinomalcsh:RC254-282Disease-Free SurvivalStomach NeoplasmsInternal medicinemedicineGeneticsHumansddc:610neoplasmsAgedDose-Response Relationship Drugbusiness.industryChemoradiotherapy Adjuvantmedicine.diseasedigestive system diseasesOxaliplatinClinical trialbusinessChemoradiotherapy
researchProduct